One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1016/j.iotech.2022.100213
Copy DOI
Export
Save
Share
Cite Journal: Immuno-Oncology and Technology |  Publication Date: Dec 1, 2022 |
 License type: cc-by-nc-nd |
Monoclonal antibody (mAb) immunogenicity manifests as ADA generation that may impact mAb efficacy and safety. Naxitamab (NAX) is a humanized GD2-binding mAb. We explored ADA formation to NAX in the ongoing phase II clinical trial 201 (NCT03363373).
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
